CMS Open Payments · Program Year 2024
J2 Bio-Pharma LLC
J2 Bio-Pharma LLC reported $1,600.00 across General Payments, Research, and Ownership to 16 physicians and teaching hospitals across 16 transactions.
- $1.6K
- All-tracks total
- 16
- Transactions
- 16
- Recipients
- #1816
- of 1,925 companies
J2 Bio-Pharma LLC reported $1,600.00 across all CMS Open Payments tracks (General + Research + Ownership) to 16 physicians and teaching hospitals in Program Year 2024 - ranking #1816 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,600.00, averaging $100.00 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer j2-bio-pharma-llc J2 Bio-Pharma LLC
$1.6K · #1816/1,925 · 0.0% industry · PY2024
- TOT $1.6K
- RANK #1816
- SHARE 0.0%
- TXN 16
- RCP 16
- CAT 1
- GEN $1.6K
- TOP1 6.3%
- PY 2024
Volume peers
Nearest volume peer: MicroPort CRM USA Inc ($1.6K)
J2 Bio-Pharma LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for J2 Bio-Pharma LLC
$1,600.00: that is what J2 Bio-Pharma LLC reported in payments to 16 physicians and teaching hospitals during Program Year 2024, spread across 16 transactions ($100.00 per transaction, $100.00 per recipient). The company sits at rank #1816 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Gift" at $1.6K, accounting for 100.0% of this company's General Payments and 16 transactions.
General Payment Breakdown by Type
"Gift" leads J2 Bio-Pharma LLC's 1-category general-payment breakdown at $1.6K, 100.0% of the reported total.
How J2 Bio-Pharma LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Gift | $1.6K | 16 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $500.00 (31.3%) of $1,600.00 in this company's General Payments records across 16 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for J2 Bio-Pharma LLC
The five named recipients with the highest reported General Payments from this company
- 1
Maria Gieron-Korthals
$100.00 across 1 reported transactions
- 2
Minodora Totoiu
$100.00 across 1 reported transactions
- 3
Chelsey Ortman
$100.00 across 1 reported transactions
- 4
Meredith Clouse
$100.00 across 1 reported transactions
- 5
Nancy Xia
$100.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as J2 Bio-Pharma LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about J2 Bio-Pharma LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with J2 Bio-Pharma LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ecs Opco 1 LLC
Meticuly Inc.
Eitan Medical North America, Inc.
Imbrium Therapeutics L.P.
G Medical Diagnostic Services, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.